CoChat

Effect of Iron Therapy on Platelet Counts in Patients with Inflammatory Bowel Disease-Associated Anemia

Open access
Kulnigg-Dabsch, Stefanie, Evstatiev, Rayko, Dejaco, Clemens, Gasche, Christoph · 2012 · PLoS ONE

The DOI matches its Crossref record; 51 of the 52 references it cites were found in a registry or an index.

Abstract

BACKGROUND AND AIMS: Secondary thrombocytosis is a clinical feature of unknown significance. In inflammatory bowel disease (IBD), thrombocytosis is considered a marker of active disease; however, iron deficiency itself may trigger platelet generation. In this study we tested the effect of iron therapy on platelet counts in patients with IBD-associated anemia. METHODS: Platelet counts were analyzed before and after iron therapy from four prospective clinical trials. Further, changes in hemoglobin, transferrin saturation, ferritin, C-reactive protein, and leukocyte counts, before and after iron therapy were compared. In a subgroup the effect of erythropoietin treatment was tested. The results were confirmed in a large independent cohort (FERGIcor). RESULTS: A total of 308 patient records were available for the initial analysis. A dose-depended drop in platelet counts (mean 425 G/L to 320 G/L; p<0.001) was found regardless of the type of iron preparation (iron sulphate, iron sucrose, or ferric carboxymaltose). Concomitant erythropoietin therapy as well as parameters of inflammation (leukocyte counts, C-reactive protein) had no effect on the change in platelet counts. This effect of iron therapy on platelets was confirmed in the FERGIcor study cohort (n=448, mean platelet counts before iron therapy: 383 G/L, after: 310 G/L, p<0.001). CONCLUSION: Iron therapy normalizes elevated platelet counts in patients with IBD-associated anemia. Thus, iron deficiency is an important pathogenetic mechanism of secondary thrombocytosis in IBD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0034520

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Primary dataset analysis. * FCM=ferric carboxymaltose. ** cumulative iron dose. Plt=platelets.
Figure 1 Primary dataset analysis. * FCM=ferric carboxymaltose. ** cumulative iron dose. Plt=platelets.CC BY · PubMed Central
Figure 2 The changes in platelet counts upon iron therapy. (A) Platelet counts pre and post iron replacement therapy according to iron preparation (black column – iron sucrose n=122, grey column – ferric carboxymaltose n=130, white column – iron sulphate n=56), p<0.001 pre vs. post for all iron preparations. (B) Mean drop in platelet counts upon intravenous iron replacement therapy according to the cumulative iron dose (p=0.002). Group 0–1200 mg n=97, group 1201–2000 mg n=103, group 2001–3600 mg n=52. Error bars represent standard deviation.
Figure 2 The changes in platelet counts upon iron therapy. (A) Platelet counts pre and post iron replacement therapy according to iron preparation (black column – iron sucrose n=122, grey column – ferric carboxymaltose n=130, white column – iron sulphate n=56), p<0.001 pre vs. post for all iron preparations. (B) Mean drop in platelet counts upon intravenous iron replacement therapy according to the cumulative iron dose (p=0.002). Group 0–1200 mg n=97, group 1201–2000 mg n=103, group 2001–3600 mg n=52. Error bars represent standard deviation.CC BY · PubMed Central
Figure 3 The changes of platelet counts and erythropoietin levels. Continuous drop in platelet counts (A, p=0.703) and serum erythropoietin levels (B, p=0.021) in Crohn's patients receiving iron sucrose (200–400 mg/week) and erythropoietin (150 mg/KG 3 times per week; light column/line) or iron sucrose (200–400 mg/week) and placebo (dark column/line). N=20 for each group. Error bars represent standard deviation.
Figure 3 The changes of platelet counts and erythropoietin levels. Continuous drop in platelet counts (A, p=0.703) and serum erythropoietin levels (B, p=0.021) in Crohn's patients receiving iron sucrose (200–400 mg/week) and erythropoietin (150 mg/KG 3 times per week; light column/line) or iron sucrose (200–400 mg/week) and placebo (dark column/line). N=20 for each group. Error bars represent standard deviation.CC BY · PubMed Central
Figure 4 The changes in platelet counts in the FERGIcor trial. (A) Platelet counts pre and post iron therapy according to the iron preparation (black column – ferric carboxymaltose n=228, grey column – iron sucrose n=220), p<0.001 pre vs. post for both iron preparations. (B) Mean drop in platelets upon iron therapy according to the cumulative iron dose (p<0.001). Group 800–1200 mg n=228, group 1201–2000 mg n=220. Error bars represent standard deviation.
Figure 4 The changes in platelet counts in the FERGIcor trial. (A) Platelet counts pre and post iron therapy according to the iron preparation (black column – ferric carboxymaltose n=228, grey column – iron sucrose n=220), p<0.001 pre vs. post for both iron preparations. (B) Mean drop in platelets upon iron therapy according to the cumulative iron dose (p<0.001). Group 800–1200 mg n=228, group 1201–2000 mg n=220. Error bars represent standard deviation.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 51 references

Cited by

Metadata

Authors
Kulnigg-Dabsch, S., Evstatiev, R., Dejaco, C., & Gasche, C.
Affiliations
Medical University of Vienna (AT)
Venue
PLoS ONE
Published
2012-04-10
Volume
7
Issue
4
Pages
e34520
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2100551670
Cited by
55
References
52
Citations by year
2026: 1 · 2025: 3 · 2024: 1 · 2023: 4 · 2022: 5 · 2021: 4 · 2020: 2 · 2018: 4 · 2017: 2 · 2016: 6 · 2015: 9 · 2014: 9 · 2013: 4 · 2012: 1
FWCI
4.90
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Fresenius Medical Care North America
  • Austrian Science Fund (P 21200)
  • Vifor Pharma
Topics
  • Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
  • Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
  • Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
Keywords
inflammatory bowel disease, iron deficiency, secondary thrombocytosis, platelet count, iron therapy, iron supplementation, erythropoietin, anemia of chronic disease, iron sucrose, ferric carboxymaltose, iron sulfate, transferrin saturation, ferritin, C-reactive protein
MeSH terms
Iron Deficiencies, Blood Platelets, C-Reactive Protein, Erythropoietin, Ferritins, Hemoglobins, Humans, Iron, Leukocyte Count, Platelet Count, Prospective Studies, Thrombocytosis, Transferrin, Inflammatory Bowel Diseases, Cohort Studies, Anemia, Iron-Deficiency, Iron Compounds

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.